Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant EV-P in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma
NCT07643519Phase 2Not yet recruiting
- Sponsor
- University of Florida
- Start
- Dec 2026
- Primary completion
- Feb 2029
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in urothelial carcinoma (UC), sponsored by University of Florida. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07643519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643519.